MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4

Lynnette Marcar, Bianca Ihrig, John Hourihan, Susan E. Bray, Philip R. Quinlan, Lee B. Jordan, Alastair M. Thompson, Ted R. Hupp, David W. Meek (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    23 Citations (Scopus)
    234 Downloads (Pure)

    Abstract

    Melanoma antigen A (MAGE-A) proteins comprise a structurally and biochemically similar sub-family of Cancer/Testis antigens that are expressed in many cancer types and are thought to contribute actively to malignancy. MAGE-A proteins are established regulators of certain cancer-associated transcription factors, including p53, and are activators of several RING finger-dependent ubiquitin E3 ligases. Here, we show that MAGE-A2 associates with MDM2, a ubiquitin E3 ligase that mediates ubiquitylation of more than 20 substrates including mainly p53, MDM2 itself, and MDM4, a potent p53 inhibitor and MDM2 partner that is structurally related to MDM2. We find that MAGE-A2 interacts with MDM2 via the N-terminal p53-binding pocket and the RING finger domain of MDM2 that is required for homo/hetero-dimerization and for E2 ligase interaction. Consistent with these data, we show that MAGE-A2 is a potent inhibitor of the E3 ubiquitin ligase activity of MDM2, yet it does not have any significant effect on p53 turnover mediated by MDM2. Strikingly, however, increased MAGE-A2 expression leads to reduced ubiquitylation and increased levels of MDM4. Similarly, silencing of endogenous MAGE-A expression diminishes MDM4 levels in a manner that can be rescued by the proteasomal inhibitor, bortezomid, and permits increased MDM2/MDM4 association. These data suggest that MAGE-A proteins can: (i) uncouple the ubiquitin ligase and degradation functions of MDM2; (ii) act as potent inhibitors of E3 ligase function; and (iii) regulate the turnover of MDM4. We also find an association between the presence of MAGE-A and increased MDM4 levels in primary breast cancer, suggesting that MAGE-A-dependent control of MDM4 levels has relevance to cancer clinically.
    Original languageEnglish
    Article numbere0127713
    Number of pages19
    JournalPLoS ONE
    Volume10
    Issue number5
    DOIs
    Publication statusPublished - 22 May 2015

    Fingerprint Dive into the research topics of 'MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4'. Together they form a unique fingerprint.

  • Cite this

    Marcar, L., Ihrig, B., Hourihan, J., Bray, S. E., Quinlan, P. R., Jordan, L. B., Thompson, A. M., Hupp, T. R., & Meek, D. W. (2015). MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4. PLoS ONE, 10(5), [e0127713]. https://doi.org/10.1371/journal.pone.0127713